REACH Trial Study
Postpartum hemorrhage (PPH) remains a major contributor to maternal mortality, particularly in low- resource settings where 99% of such deaths occur. Oxytocin, the World Health Organization’s recommended first-line uterotonic for PPH treatment, requires cold chain storage—posing significant challenges in these environments. While misoprostol is heat-stable and widely available, it has been shown to be less effective than oxytocin. This underscores the urgent need for an alternative uterotonic that combines the efficacy of oxytocin with the storage advantages of misoprostol.
- Read more about REACH Trial Study
- Log in to post comments